Xeris Pharmaceuticals
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $54,268 | $48,065 | $40,638 | $44,390 |
Gross Profit | 40,675 | 37,565 | 31,956 | 34,109 |
EBITDA | -8,152 | -3,138 | -8,427 | -3,349 |
EBIT | -11,276 | -6,292 | -11,641 | -6,608 |
Net Income | -15,738 | -15,005 | -18,980 | -13,390 |
Net Change In Cash | 54,268 | 48,065 | 40,638 | 44,390 |
Free Cash Flow | -8,392 | -10,745 | -20,467 | 6,154 |
Cash | 59,232 | 57,604 | 62,690 | 67,449 |
Basic Shares | 148,993 | 148,345 | 140,513 | 138,124 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $163,914 | $110,248 | $110,248 | $20,155 |
Gross Profit | 135,269 | 87,614 | 87,614 | 10,827 |
EBITDA | -23,735 | -69,314 | -113,666 | -80,581 |
EBIT | -36,895 | -81,982 | -115,545 | -83,546 |
Net Income | -62,255 | -94,660 | -94,660 | -91,140 |
Net Change In Cash | 163,914 | 110,248 | 110,248 | 20,155 |
Cost of Revenue | 18,079 | |||
Free Cash Flow | -49,286 | -103,415 | -96,620 | -80,935 |
Cash | 67,449 | 121,966 | 121,966 | 37,598 |
Basic Shares | 137,674 | 135,628 | 79,027 | 26,110 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.11 |
2024-06-30 | -$0.10 |
2024-03-31 | -$0.14 |
2023-12-31 | -$0.10 |
